61 related articles for article (PubMed ID: 36529989)
1. Extensive genomic analysis in patients with
Jacobsen IC; Spanggaard I; Højgaard M; Belcaid L; Qvortrup C; Yde CW; Schmidt AY; Nielsen FC; Willemoe GL; Dam MS; Lassen U; Staal Rohrberg K
Acta Oncol; 2022 Dec; 61(12):1499-1506. PubMed ID: 36529989
[TBL] [Abstract][Full Text] [Related]
2. KRAS Allelic Variants in Biliary Tract Cancers.
Moffat GT; Hu ZI; Meric-Bernstam F; Kong EK; Pavlick D; Ross JS; Murugesan K; Kwong L; De Armas AD; Korkut A; Javle M; Knox JJ
JAMA Netw Open; 2024 May; 7(5):e249840. PubMed ID: 38709532
[TBL] [Abstract][Full Text] [Related]
3. Next batter up! Targeting cancers with KRAS-G12D mutations.
Zeissig MN; Ashwood LM; Kondrashova O; Sutherland KD
Trends Cancer; 2023 Nov; 9(11):955-967. PubMed ID: 37591766
[TBL] [Abstract][Full Text] [Related]
4. Whole-exome sequencing of secondary tumors arising from nevus sebaceous revealed additional genomic alterations besides RAS mutations.
Kim YS; Park GS; Chung YJ; Lee JH
J Dermatol; 2023 Aug; 50(8):1072-1075. PubMed ID: 36938660
[TBL] [Abstract][Full Text] [Related]
5. Precision medicine for pancreatic cancer: Characterizing the clinico-genomic landscape and outcomes of KRAS G12C-mutated disease.
Keane F; Chou JF; Walch H; Schoenfeld J; Singhal A; Cowzer D; Harrold E; O'Connor C; Park W; Varghese A; El Dika I; Balogun F; Yu KH; Capanu M; Schultz N; Yaeger R; O'Reilly EM
J Natl Cancer Inst; 2024 May; ():. PubMed ID: 38702822
[TBL] [Abstract][Full Text] [Related]
6. Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers.
Jiagge E; Jin DX; Newberg JY; Perea-Chamblee T; Pekala KR; Fong C; Waters M; Ma D; Dei-Adomakoh Y; Erb G; Arora KS; Maund SL; Njiraini N; Ntekim A; Kim S; Bai X; Thomas M; van Eeden R; Hegde P; Jee J; Chakravarty D; Schultz N; Berger MF; Frampton GM; Sokol ES; Carrot-Zhang J
Cancer Cell; 2023 Nov; 41(11):1963-1971.e3. PubMed ID: 37890492
[TBL] [Abstract][Full Text] [Related]
7. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C
Eur J Cancer; 2023 Jul; 187():174-184. PubMed ID: 37167765
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genomic landscape of RAS mutations in gynecologic cancers.
Son J; Zhang Y; Lin H; Mirallas O; Alvarez Ballesteros P; Nardo M; Clark N; Hillman RT; Campbell E; Holla V; Johnson AM; Biter AB; Yuan Y; Cobb LP; Gershenson DM; Jazaeri AA; Lu KH; Soliman PT; Westin SN; Euscher ED; Lawson BC; Yang RK; Meric-Bernstam F; Hong DS
Clin Cancer Res; 2024 Apr; ():. PubMed ID: 38687597
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of panel gene sequencing on therapy of advanced cancers of the digestive system: a retrospective, single center study.
Dreikhausen L; Klupsch A; Wiest I; Xiao Q; Schulte N; Betge J; Boch T; Brochhausen C; Gaiser T; Hofheinz RD; Ebert M; Zhan T
BMC Cancer; 2024 Apr; 24(1):526. PubMed ID: 38664720
[TBL] [Abstract][Full Text] [Related]
10. Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations.
Passaro A; Attili I; Rappa A; Vacirca D; Ranghiero A; Fumagalli C; Guarize J; Spaggiari L; de Marinis F; Barberis M; Guerini-Rocco E
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946519
[TBL] [Abstract][Full Text] [Related]
11. Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience.
Porta C; Pradelli L; Sicari E; Castellani S; Sivakumar S; Sokol E; Montesion M; Wieland T; Rambichler J; Minari R; Tiseo M
Lung Cancer; 2023 Nov; 185():107359. PubMed ID: 37703610
[TBL] [Abstract][Full Text] [Related]
12. YB-1 activating cascades as potential targets in KRAS-mutated tumors.
Khozooei S; Veerappan S; Toulany M
Strahlenther Onkol; 2023 Dec; 199(12):1110-1127. PubMed ID: 37268766
[TBL] [Abstract][Full Text] [Related]
13. Effects of KRAS Genetic Interactions on Outcomes in Cancers of the Lung, Pancreas, and Colorectum.
Grabski IN; Heymach JV; Kehl KL; Kopetz S; Lau KS; Riely GJ; Schrag D; Yaeger R; Irizarry RA; Haigis KM
Cancer Epidemiol Biomarkers Prev; 2024 Jan; 33(1):158-169. PubMed ID: 37943166
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Genomic Profiling and Therapeutic Implications for Patients with Advanced Cancers: The Experience of an Academic Hospital.
Teuwen LA; Roets E; D'Hoore P; Pauwels P; Prenen H
Diagnostics (Basel); 2023 May; 13(9):. PubMed ID: 37175010
[TBL] [Abstract][Full Text] [Related]
15. Genomic landscape and actionable mutations of brain metastases derived from non-small cell lung cancer: A systematic review.
Andrews LJ; Thornton ZA; Saleh R; Dawson S; Short SC; Daly R; Higgins JPT; Davies P; Kurian KM
Neurooncol Adv; 2023; 5(1):vdad145. PubMed ID: 38130901
[TBL] [Abstract][Full Text] [Related]
16. Role of Tumor Molecular Profiling With FoundationOne®CDx in Advanced Solid Tumors: A Single-Centre Experience From Romania.
Popa AM; Stejeroiu MA; Iaciu C; Olaru M; Orlov Slavu C; Parosanu A; Stanciu IM; Pirlog C; Pavel S; Nitipir C
Cureus; 2023 Dec; 15(12):e50709. PubMed ID: 38111812
[TBL] [Abstract][Full Text] [Related]
17. Concomitant Mutations G12D and G13D on the Exon 2 of the KRAS Gene: Two Cases of Women with Colon Adenocarcinoma.
De Falco E; Pacini L; Bastianelli D; Spinelli GP; Spoto C; Veltri E; Calogero A
Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33917572
[TBL] [Abstract][Full Text] [Related]
18. Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer.
Suehnholz SP; Nissan MH; Zhang H; Kundra R; Nandakumar S; Lu C; Carrero S; Dhaneshwar A; Fernandez N; Xu BW; Arcila ME; Zehir A; Syed A; Brannon AR; Rudolph JE; Paraiso E; Sabbatini PJ; Levine RL; Dogan A; Gao J; Ladanyi M; Drilon A; Berger MF; Solit DB; Schultz N; Chakravarty D
Cancer Discov; 2024 Jan; 14(1):49-65. PubMed ID: 37849038
[TBL] [Abstract][Full Text] [Related]
19. Pediatric Precision Medicine at the National Cancer Center Japan: Prospective Genomic Study of Pediatric Patients with Cancer as Part of the TOP-GEAR Project.
Tao K; Yamazaki F; Kubo T; Sunami K; Kumamoto T; Arakawa A; Sugiyama M; Watanabe Y; Nakajima M; Shirakawa N; Tanimura K; Koyama T; Hirata M; Sudo K; Tanabe N; Watanabe T; Yoshida T; Kitami M; Yoshida A; Yatabe Y; Nakano Y; Ohira M; Kamijo T; Nakazawa A; Kato M; Ichimura K; Kohno T; Yamamoto N; Hishiki T; Ichikawa H; Ogawa C
JCO Precis Oncol; 2023 Jul; 7():e2200266. PubMed ID: 37410973
[TBL] [Abstract][Full Text] [Related]
20. Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens.
Karimpour M; Totonchi M; Behmanesh M; Montazeri H
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37863651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
